Keep Rectal Cancer Away®

Who is at risk

• Age — risk rises after 45, and cases in younger adults are increasing.
• Family history of colorectal cancer or advanced polyps.
• Lynch syndrome and other inherited conditions.
• Inflammatory bowel disease of long duration.
• Smoking, heavy alcohol, obesity and inactivity.
• Prior pelvic radiation or a previous colorectal cancer.

Finding it early

Screening works here better than almost anywhere in oncology, because it does not just find cancer early — it removes the polyps that would have become cancer. That is prevention, not just detection.

The U.S. Preventive Services Task Force recommends screening for everyone at average risk from age 45 to 75 (USPSTF, 2021), and individualized decisions from 76 to 85. Start earlier if you have a family history, inflammatory bowel disease, or a known genetic syndrome such as Lynch.

Your options: colonoscopy every 10 years (finds and removes polyps in the same visit); stool-based tests (FIT yearly, or stool DNA every 1–3 years) which are easy and done at home but require a colonoscopy if positive; or CT colonography every 5 years. The best test is the one you will actually do.

Symptoms that should not wait for a screening date — blood in the stool or on the paper, a lasting change in bowel habit, narrow stools, cramping that does not settle, unexplained weight loss, or unexplained iron-deficiency anemia. Rectal bleeding is often hemorrhoids; it is also the most commonly ignored early sign. Get it looked at.

Colorectal cancer is rising in adults under 50. If you are 35 and bleeding, you still deserve a proper evaluation.

How it’s diagnosed

Diagnosis is usually made at colonoscopy: the polyp or tumor is seen and biopsied in the same visit. You are sedated and generally remember little of it; the preparation the day before is the part people mind.

Once cancer is confirmed, staging usually involves CT of the chest, abdomen and pelvis, a blood test called CEA that can be used as a baseline for later monitoring, and — for rectal cancer specifically — a pelvic MRI, which is the study that shows how close the tumor is to the outer edge of the rectum.

Tumor testing matters: MMR/MSI status is checked on essentially all colorectal cancers, because a mismatch-repair-deficient tumor may respond dramatically to immunotherapy and can also point to Lynch syndrome, which has implications for your relatives. RAS and BRAF testing guide drug choice in advanced disease.

For rectal cancer the pelvic MRI is the pivotal study. It shows how deeply the tumor has grown, whether it threatens the outer margin, and whether nodes are involved — and those findings decide whether radiation comes before surgery. A rectal ultrasound is sometimes used for early tumors.

Staging explained simply

The same T, N and M system applies. In rectal cancer one extra measurement matters enormously: the distance between the tumor and the circumferential resection margin — the outer edge of the tissue the surgeon can remove. A threatened margin usually means treatment before surgery.

Grading and biology

Stage is how far it has travelled; grade is how abnormal the cells look. Low-grade (well-differentiated) cells resemble normal tissue and generally behave more predictably; high-grade cells look disordered and tend to move faster.

Two other features are reported and worth asking about: whether cancer is seen in small blood or lymph vessels (lymphovascular invasion), and how many lymph nodes were examined — a thorough node count makes the stage more reliable. MMR/MSI status, described above, often influences treatment more than grade does.

How it’s treated

Radiation has a central role here, usually given before surgery to shrink the tumor, sterilize the margin and lower the chance of it coming back in the pelvis. Two schedules are common: a short course of five treatments, or a longer course of about five to six weeks given with chemotherapy.

Total neoadjuvant therapy (TNT) — giving both the radiation and the chemotherapy before surgery — has become a standard approach. It gets the full treatment delivered when people tolerate it best, and it produces more complete responses.

Watch and wait. When a tumor disappears completely on scans, examination and endoscopy after treatment, some patients can be monitored closely instead of having surgery — preserving the rectum. This requires a centre committed to intensive surveillance and is not right for everyone, but for the right person it is a genuinely different life.

Surgery, when needed, removes the rectum along with its surrounding fatty envelope. Whether a temporary or permanent stoma is required depends mostly on how close the tumor sits to the anal sphincter.

Where CureRays fits: radiation planning for the pelvis is detailed work, and the difference between a good plan and an adequate one shows up in long-term bowel, bladder and sexual function. That is our specialty.

What the guidelines say

In broad strokes: stage with pelvic MRI; for locally advanced tumors give radiation and chemotherapy before surgery, increasingly as total neoadjuvant therapy; perform surgery that removes the rectum within its intact envelope; consider watch-and-wait only with a complete clinical response and rigorous surveillance; test every tumor for mismatch repair status.

Your team will follow national guidelines such as those from the National Comprehensive Cancer Network (NCCN). The description above is a plain-language overview of the general approach, not the guideline itself — your own plan may reasonably differ. NCCN publishes free NCCN Guidelines for Patients® written for exactly this purpose.

Outcomes and odds of cure

Source: NCI SEER Cancer Stat Facts: Colorectal Cancer, SEER 22 (excluding IL/MA), 2014–2020. SEER reports colon and rectal cancers together, so these figures cover both.

Rectal-specific survival differs somewhat from these combined figures. Ask your team for numbers that match your own stage and treatment plan.

These are population statistics from the National Cancer Institute's SEER program. They describe large groups of people, not any one person, and they lag current treatment by several years. They cannot predict what will happen to you.

Side effects and how we watch for them

During pelvic radiation: loose or urgent bowel movements, irritation on urination, fatigue that builds over the weeks, and skin redness in the treated area, particularly in the crease. Most of this settles within weeks of finishing.

Later: some people have lasting changes in bowel frequency or urgency, and radiation to the pelvis can affect fertility and sexual function — ask about fertility preservation before treatment starts if that matters to you. Modern planning keeps dose off the small bowel and bladder as much as the anatomy allows.

How it is assessed: graded on a standard scale at each visit so changes are measured, not guessed. Report bleeding, fever, or inability to keep fluids down promptly.

Follow-up, remission and survivorship

Remission means no detectable cancer. After rectal cancer, surveillance is more intensive than for many cancers — and much more so if you are on a watch-and-wait pathway, where the whole strategy depends on catching any regrowth early.

Typical follow-up: visits and CEA every few months for two to three years, periodic CT, colonoscopy at one year, and for watch-and-wait, rectal examination and endoscopy every few months at first.

Survivorship after pelvic treatment deserves honest conversation: bowel urgency, sexual function and fertility are all commonly affected and all have treatments. They are hard to raise and worth raising.

Questions people actually ask

Informational only, not medical advice — confirm with your care team.

Go deeper on colorectal cancer

Read the full plain-language guide, or talk with our radiation team about your pelvic MRI.

Full colorectal cancer guide